Skip to search formSkip to main contentSkip to account menu

STX209

Known as: STX-209 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Several electrophysiological parameters, including the auditory evoked response component M50/M100 latencies and the phase… 
2017
2017
onists have been tested in ASD associated with fragile X syndrome, and showed promise in a subgroup of patients. GABAergic agents… 
2015
2015
  • Asher Mullard
  • Nature Reviews Drug Discovery
  • 2015
  • Corpus ID: 39513057
The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial… 
Highly Cited
2014
Highly Cited
2014
STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory… 
Review
2014
Review
2014
  • R. Frye
  • Drug, healthcare and patient safety
  • 2014
  • Corpus ID: 15287818
Autism spectrum disorder (ASD) is a behaviorally defined disorder which has increased in prevalence over the last two decades… 
Review
2013
Review
2013
  • C. Woolf
  • The Lancet Neurology
  • 2013
  • Corpus ID: 8697382
Highly Cited
2012
Highly Cited
2012
Administration of a selective GABAB agonist to individuals with fragile X syndrome improves their deficits in social avoidance, a… 
Highly Cited
2012
Highly Cited
2012
Pharmacological activation of the GABAB receptor with arbaclofen in a mouse model of fragile X syndrome corrects neuronal defects… 
2012
2012
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for… 
Review
2011
Review
2011
  • C. Hopkins
  • ACS chemical neuroscience
  • 2011
  • Corpus ID: 9939453
STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical…